TRIFLURIDINE/TIPIRACIL (FTD/TPI) with or without bevacizumab in previously treated patients with esophago-gastric adenocarcinoma, a randomised phase III trialResearch in context

Summary: Background: Trifluridine-tipiracil has shown a survival benefit compared with placebo in patients with chemorefractory metastatic esophago-gastric adenocarcinoma. We aimed to compare the efficacy of trifluridine-tipiracil plus bevacizumab vs trifluridine-tipiracil monotherapy in pre-treate...

Полное описание

Библиографические подробности

Главные авторы:	Lene Baeksgaard Jensen, Mette Yilmaz, Marianne Nordsmark, Sören Möller, Ida Coordt Elle, Morten Ladekarl, Camilla Qvortrup, Per Pfeiffer
Формат:	Artigo
Язык:	Inglês
Опубликовано:	Elsevier 2024-04-01
Серии:	EClinicalMedicine
Предметы:	Gastroesophageal Cancer Metastatic Trifluridine-tipiracil Bevacizumab
Online-ссылка:	http://www.sciencedirect.com/science/article/pii/S2589537024001007
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!